News
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook ...
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback